1. |
Reviewing therapies for primary biliary cirrhosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Don't rule out epidermal growth factor receptor antagonists |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Therapeutic options for viral lower respiratory tract infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Telithromycin less costly than clarithromycin for CAP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 5-6
P Hunter,
Preview
|
|
摘要:
Telithromycin is a ketolide antibacterial agent with a mode of action similar to that of the related macrolides. Its spectrum of antibacterial activity, like that of clarithromycin, is well suited for use in the treatment of community-acquired pneumonia (CAP), as it is active against most common causative bacterial pathogens, including atypical and intracellular species. In addition, it retains activity against a number of strains of bacteria resistant to conventional macrolides. It has advantageous pharmacokinetic properties, only requiring once-daily dosing. CAP is a common and widespread disease which carries a high economic burden of treating both inpatients and outpatients. A study comparing the economic effect of treatment with telithromycin with that of clarithromycin in adult patients with confirmed mild-to-moderate acute CAP was presented at the 13th European Congress of Clinical Microbiology and Infectious Diseases [Glasgow, Scotland; May 2003].1The results showed that the overall healthcare costs associated with telithromycin were lower than those associated with clarithromycin.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
NSAID chemoprevention warranted in Barrett's oesophagus? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Tailored pharmacokinetic dosing of IV α1-antitrypsin augmentation therapy"markedly reduces"the annual drug cost among patients with α1-antitrypsin deficiency in Sweden, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Cefepime less costly vs combination therapy in febrile neutropenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Alvocidib [flavopiridol] has modest activity as a single agent against untreated or relapsed mantle cell lymphoma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
VEGF gene therapy for restenosis prevention |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Head to head: ziprasidone has advantages over risperidone in schizophrenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1395,
2003,
Page 11-13
RM Poole,
Preview
|
|
摘要:
Ziprasidone ['Geodon'] is as effective as risperidone ['Risperdal'], but has a more favourable tolerability profile, according to a study presented at the 156th Annual Meeting of the American Psychiatric Association [San Francisco, US; May 2003]. In this study, the first double-blind direct comparison of the two atypical antipsychotics, treatment with either ziprasidone or risperidone for up to 1 year provided"robust"and durable improvements in symptoms, with no significant differences between the two drugs in primary and secondary efficacy measures. However, patients treated with risperidone experienced significantly greater overall discomfort due to movement disorders and had higher incidences of weight gain and elevated prolactin levels than ziprasidone recipients."These findings of comparable efficacy but better tolerability with ziprasidone versus risperidone carry implications for therapeutic adherence and long-term successful outcomes,"commented the researchers. In other presentations, switching to ziprasidone from risperidone, olanzapine ['Zyprexa'], or conventional antipsychotics was shown to provide improvements in social functioning and negative symptoms, suggesting the potential for improved outcomes and quality of life.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|